Emergent BioSolutions Files 8-K

TL;DR

Emergent BioSolutions filed a routine 8-K, no major news.

AI Summary

Emergent BioSolutions Inc. filed an 8-K on June 20, 2024, to report on other events and financial statements. The filing does not contain specific details about new agreements, material events, or financial performance beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates routine corporate reporting by Emergent BioSolutions Inc. to the SEC, without disclosing specific material events that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain information about significant new risks or material adverse events.

Key Players & Entities

• Emergent BioSolutions Inc. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• 300 Professional Drive, Gaithersburg, Maryland 20879 (location) — Principal executive offices address
• 240-631-3200 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
• $30 million — mden for a total value of approximately $30 million. Approximately 350 of the Company's emp

Filing Documents

• ebs-20240620.htm (8-K) — 30KB
• ebscenturyrelease.htm (EX-99.1) — 13KB
• image.jpg (GRAPHIC) — 7KB
• 0001367644-24-000112.txt ( ) — 181KB
• ebs-20240620.xsd (EX-101.SCH) — 2KB
• ebs-20240620_lab.xml (EX-101.LAB) — 22KB
• ebs-20240620_pre.xml (EX-101.PRE) — 13KB
• ebs-20240620_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On June 20, 2024, Emergent BioSolutions Inc. ("Emergent") issued a press release announcing the entry into the Agreement described below in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto. The information contained in this Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing, under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On June 20, 2024 , Cangene bioPharma LLC ("Cangene"), a subsidiary of Emergent (together with Cangene, the "Company"), entered into an Asset Purchase Agreement (the "Agreement") with Bora Pharmaceuticals Injectibles Inc., a subsidiary of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), under which the Company will sell its drug product facility in Baltimore-Camden for a total value of approximately $30 million. Approximately 350 of the Company's employees are expected to join Bora as part of the transaction. Closing of the transaction is subject to the satisfaction or waiver of customary closing conditions. The Company and Bora have made customary representations, warranties and covenants in the Agreement. Between the date of the Agreement and the closing of the transaction the Company has agreed to use commercially reasonable efforts to operate the Baltimore-Camden facility in the ordinary course, consistent with past practices. The Agreement also contains customary indemnification provisions and termination rights for each of the parties, including if the transaction has not closed on or before September 30, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on June 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: June 20, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR